Pharma News

An innovative temperature-compensation mechanism for oscillating chemical reactions based on temperature-responsive gels has been recently reported by researchers at Tokyo Tech. Their experimental findings, alongside a detailed mathematical analysis, hint at the possibility that circadian rhythms found in nature may all rely on a similar mechanism, allowing their period to remain independent of temperature.

The World Health Organization (WHO) and Gilead Sciences have signed a new agreement for the donation of 304,700 vials of AmBisome (liposomal amphotericin B for injection), for the treatment of visceral leishmaniasis in countries most impacted by the disease, extending their previous agreement to 2025.

Glenmark Pharmaceuticals Ltd, an innovation-driven, global pharmaceutical company, is the first to launch in India a unique I.V. injection formulation, AKYNZEO® I.V., for the prevention of chemotherapy-induced nausea and vomiting (CINV), under an exclusive licensing agreement with Helsinn, a Swiss biopharma group company.

Granules India Limited announced that the US Food & Drug Administration (US FDA) has approved the Abbreviated New Drug Application (ANDA) filed by Granules Pharmaceuticals, Inc (GPI)., a wholly-owned foreign subsidiary of the company, for Amphetamine Mixed Salts, 5mg, 10mg, 15mg, 20mg, 25mg, and 30mg Extended-Release (ER) capsules. It is bioequivalent to the reference listed drug product (RLD), Adderall XR® Extended-Release capsules of Takeda Pharmaceuticals USA Inc.

Researchers have found that the drug rilmenidine can extend lifespan and slow ageing.

Published in Aging Cell, the findings show that animals treated with rilmenidine, currently used to treat hypertension, at young and older ages increases lifespan and improves health markers, mimicking the effects of caloric restriction.

Bacteria of the genus Enterobacter are among the most dangerous bacteria associated with hospital infections worldwide. Some of their representatives are highly resistant to commonly used antibiotics, so that the reserve antibiotic colistin is increasingly used as a last resort therapy option. To avoid unnecessary reliance on colistin and risk increasing resistance, bacteria are tested for sensitivity or resistance to colistin before recommending treatment. However, commonly used tests for Enterobacter are not reliable.

Sun Pharmaceutical Industries Limited  and Concert Pharmaceuticals, Inc announced that they have executed a definitive agreement under which Sun Pharma will acquire all outstanding shares of Concert through a tender offer for an upfront payment of 8.00 USD per share of common stock in cash, or 576 USD million in equity value.

The precious chemistry of a plant used for 2,000 years in traditional Chinese medicine has been unlocked in a project that raises the prospect of rapid access to a wide array of therapeutic drugs.

Carried out by CEPAMS – a partnership between the Chinese Academy of Sciences and the John Innes Centre – the project has successfully delivered a high-quality reference genome of the mint-family member Scutellaria baicalensis Georgi.

Researchers have designed the first ‘living medicine’ to treat lung infections. The treatment targets Pseudomonas aeruginosa, a type of bacteria which is naturally resistant to many types of antibiotics and is a common source of infections in hospitals.